- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01203644
Evaluation of the Safety, Efficacy, and Pharmacokinetics of SKY0402 in Subjects Undergoing Inguinal Hernia Repair
4 januari 2021 uppdaterad av: Pacira Pharmaceuticals, Inc
A Phase 2, Multicenter, Randomized, Double Blind, Dose Escalating/ De Escalating Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of a Single Dose of Sustained Release Encapsulated Bupivacaine (SKY0402) in the Management of Postoperative Pain in Subjects Undergoing Inguinal Hernia Repair
The primary objective of this study was to determine the appropriate dose of SKY0402 for the management of postoperative pain following inguinal hernia repair.
This study evaluated the safety, efficacy, and pharmacokinetics of SKY0402 compared with a 100 mg dose of bupivacaine HCl for the treatment of postoperative pain in subjects undergoing inguinal hernia repair.
Study drug was administered by surgical wound infiltration at the end of the hernia repair procedure.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Detaljerad beskrivning
SKY0402 was administered in a dose escalating/de-escalating fashion, with a low starting dose in Cohort 1 that was to be increased or decreased in subsequent cohorts based on safety and analgesic effects.
The decision to proceed to the next cohort (i.e., increase or decrease the dose) was made by a Cohort Data Review Committee following a review of the data from the previous cohort.
Subjects were randomized to receive either SKY0402 or bupivacaine HCl at a ratio of 1:1 in Cohort 1 and at a ratio of 3:1 in subsequent cohorts.
The dose of bupivacaine HCl (100 mg) remained constant for all cohorts.
Studietyp
Interventionell
Inskrivning (Faktisk)
76
Fas
- Fas 2
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år och äldre (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Manlig
Beskrivning
Inclusion Criteria:
- Males ≥18 years of age at the Screening visit.
- Scheduled to undergo unilateral inguinal hernia repair under general anesthesia, using an open, tension free procedure (e.g., Lichtenstein technique with or without mesh).
- American Society of Anesthesiology (ASA) Physical Class 1 or 2.
- Able and willing to comply with all study visits and procedures.
- Capable of speaking and understanding the local language sufficiently to provide responses to pain assessment scales.
- Willing and capable of providing written informed consent.
Exclusion Criteria:
- Clinically significant electrocardiogram abnormalities at Screening or on Day 1 (pre administration).
- Albumin and/or alpha 1 acid glycoprotein (AAG) below normal levels.
- Current or historical evidence of any clinically significant disease or condition that, in the opinion of the Investigator, might have increased the risk of surgery or complicated the subject's postoperative course.
- Opioid medication usage during the 7 day period preceding the administration of study drug.
- Current medical conditions that could have required treatment with analgesic medications in the postoperative period for pain that was not surgically related (e.g., rheumatoid arthritis).
- Body mass index >30 kg/m^2
- Body weight <60 kg.
- History of hypersensitivity or idiosyncratic reaction to amide type local anesthetic agents.
- History of hypersensitivity, idiosyncratic reactions, and other contraindications to the pain control agents (opioid or non-opioid) anticipated to be used postoperatively. These contraindications may have included: angioedema and bronchospastic reactivity to non steroidal anti inflammatory drug, peptic ulcer (active within the last three months), hepatic or renal insufficiency.
- Coagulation disorders or ongoing anticoagulation treatment.
- Administration of an investigational drug within 30 days or five half lives (of elimination), whichever was longer, prior to study drug administration.
- Suspected or known history of substance abuse and/or alcoholism.
- Clinically significant complications during the hernia repair surgery (e.g., excessive bleeding), which might have rendered the subject medically unstable or might have complicated the subject's postoperative course.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Bupivacaine HCl
(e.g., Marcaine with epinephrine 1:200,000) is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402
|
Single dose of SKY0402 administered locally into the surgical wound.
|
|
Aktiv komparator: SKY0402
Low dose, low-mid dose, mid-dose, and high dose
|
Single dose of bupivacaine HCl (100 mg) administered locally into the surgical wound.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Time to First Use of Supplemental Pain Medication
Tidsram: Through 96 hours postdose
|
The primary efficacy endpoint was the time to first use of supplemental pain medication (opioid or non-opioid) postoperatively for surgical wound pain
|
Through 96 hours postdose
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Adverse Events
Tidsram: Through 30 days postdose
|
Safety assessments included monitoring of treatment-emergent adverse events
|
Through 30 days postdose
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Utredare
- Studierektor: Kay Warnott, RN, ACNP, Pacira Pharmaceuticals, Inc
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 december 2004
Primärt slutförande (Faktisk)
1 januari 2006
Avslutad studie (Faktisk)
1 december 2006
Studieregistreringsdatum
Först inskickad
15 september 2010
Först inskickad som uppfyllde QC-kriterierna
15 september 2010
Första postat (Uppskatta)
16 september 2010
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
25 januari 2021
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
4 januari 2021
Senast verifierad
1 januari 2021
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- SKY0402-C-201
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .